# Biopharmaceuticals Contract Manufacturing Market

> Biopharmaceuticals Contract Manufacturing Market Research Report: Size, Share, Trend Analysis By Service Type (Process Development, Manufacturing, Quality Assurance, Regulatory Affairs), By Product Type (Monoclonal Antibodies, Vaccines, Recombinant Proteins, Gene Therapy Products, Cell Therapy Products), By Therapeutic Area (Oncology, Infectious Diseases, Cardiovascular, Autoimmune Disorders, Neurology), By Client Type (Pharmaceutical Companies, Biotechnology Companies, Academic Institutions, Research Organizations) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth Outlook & Industry Forecast 2026 To 2035

- **Forecast Period:** 2026-2035
- **CAGR:** 12.45%
- **2025:** USD 44.90 Billion
- **2035:** USD 144.96 Billion
- **Key Players:** Lonza Group, Samsung Biologics, WuXi Biologics, Thermo Fisher Scientific (Patheon), Boehringer Ingelheim BioXcellence, Fujifilm Diosynth Biotechnologies, Catalent (Novo Holdings), AGC Biologics

**Report ID:** MRFR/HC/41886-HCR · **Pages:** 200 · **Author:** Rahul Gotadki & Nidhi Mandole · **Last Updated:** November 03, 2026

**URL:** https://www.marketresearchfuture.com/reports/biopharmaceuticals-contract-manufacturing-market-43552

---

## Market Summary

## Biopharmaceuticals Contract Manufacturing Market Summary

The [Biopharmaceuticals](https://www.marketresearchfuture.com/reports/biopharmaceuticals-market-8439) Contract Manufacturing Market was valued at USD 44.90 billion in 2025 and is projected to reach USD 50.42 billion in 2026, rising to USD 144.96 billion by 2035 at a CAGR of 12.45% over 2026–2035. Two catalysts anchor that trajectory. Novo Holdings closed its USD 16.5 billion acquisition of Catalent in December 2024 [1], signalling how strategically buyers now value fill-finish and drug-substance capacity. In the United States, the BIOSECURE Act, which passed the House in September 2024 [2], pushed sponsors to re-examine supplier geography and dual-source critical programs.

Production technology is shifting just as quickly. Fixed stainless-steel trains built around single blockbuster products are giving way to modular single-use suites, intensified perfusion processes, and continuous downstream steps endorsed by the ICH Q13 guideline [3]. Fujifilm Diosynth Biotechnologies committed an additional USD 1.2 billion to its Holly Springs, North Carolina campus in 2024, while Samsung Biologics opened its 180,000-liter Plant 5 in 2025 [5]. Both investments favor large-scale mammalian capacity with flexible changeover.

North America leads with a 38.6% share in 2025, supported by the deepest biotech pipeline and FDA-inspected capacity. Asia Pacific is the fastest-growing region at a 15.1% CAGR, driven by South Korean and Indian build-outs. Europe ranks second in the Biopharmaceuticals Contract Manufacturing Market, backed by Swiss, German, and Irish manufacturing clusters. Over the next decade, capacity location will matter as much as capacity scale.

## Key Report Takeaways

### • By Product Type

- Antibodies (mAbs & ADCs) hold a 35.4% share of the Biopharmaceuticals Contract Manufacturing Market in 2025, reflecting oncology and immunology volume.
- Other Biologics, which include cell and [gene therapy](https://www.marketresearchfuture.com/reports/gene-therapy-market-8399) vectors, expand at a 16.5% CAGR through 2035.
- Peptides/Proteins generate USD 9.43 billion in 2025, lifted by GLP-1 demand.

### • By Service Type

- cGMP Drug Substance Manufacturing accounts for a 46.8% share of the Biopharmaceuticals Contract Manufacturing Market.
- Process Development grows at a 14.6% CAGR as early-stage sponsors outsource CMC work.

### • By Expression System

- Mammalian systems command a 58.6% share in 2025.
- Insect & Plant platforms post a 13.4% CAGR from a small base.

### • By Development Phase

- Phase III & Commercial work represents a 61.3% share in 2025.
- Pre-clinical programs rise at a 14.1% CAGR on venture-funded pipelines.

### • By Region

- North America leads the Biopharmaceuticals Contract Manufacturing Market with a 38.6% share.
- Asia Pacific is the fastest-growing region at a 15.1% CAGR.
- Europe generates USD 12.75 billion in 2025.

## Market Size and Forecast (2026–2035)

Historical values combine audited CDMO segment revenues from company filings, regulatory inspection databases, and sponsor outsourcing disclosures, reconciled through bottom-up capacity modeling and top-down validation against biologics sales. Forecast values for the Biopharmaceuticals Contract Manufacturing Market incorporate announced capacity additions, pipeline phase-transition probabilities, and patent-expiry schedules [6][7].

## Market Drivers

## Driver Impact Analysis

| Driver | ~% Impact on CAGR | Geographic Relevance | Impact Timeline | Ref |
| --- | --- | --- | --- | --- |
| Biologics pipeline expansion and small-biotech outsourcing | +2.6% | Global, led by North America | Long-term (≥4 yr) |   |
| Supply-chain diversification and reshoring | +1.8% | North America, Europe, India | Medium-term (2–4 yr) | [2] |
| Biosimilar wave from mAb patent expiries | +1.5% | Global | Medium-term (2–4 yr) | [9] |
| Complexity of ADCs and bispecifics | +1.4% | North America, Europe, China | Long-term (≥4 yr) |   |
| Single-use and continuous manufacturing adoption | +1.1% | Global | Short-term (≤2 yr) | [3] |
| Government biomanufacturing programs | +0.9% | US, India, South Korea | Medium-term (2–4 yr) | [11] |

### Biologics Pipeline Expansion and Small-Biotech Outsourcing

The FDA's Center for Drug Evaluation and Research approved 50 novel drugs in 2024, with biologics a substantial share. Most of the next wave comes from emerging biotechs that own no plants and outsource nearly all CMC activities to conserve cash. That structural dependence across the Biopharmaceuticals Contract Manufacturing Market turns every successful Phase II readout into a multi-year manufacturing contract. It also rewards CDMOs that can carry a molecule from cell-line development through commercial supply without a site transfer.

### Supply-Chain Diversification and Reshoring

BIOSECURE legislation, which passed the House 306–81 in September 2024 [2], made sponsors map exposure to specific Chinese suppliers. Even before any final enactment, procurement teams began qualifying second sources in the US, Europe, South Korea, and India. Lonza's USD 1.2 billion purchase of Genentech's Vacaville site [12] shows how Western capacity gets repriced when buyers seek politically resilient supply chains. Qualification cycles of 18–30 months make this a medium-term driver.

### Biosimilar Wave from mAb Patent Expiries

Major antibodies including Keytruda, Opdivo, and Darzalex lose key exclusivity protections between 2028 and 2031 [9]. Biosimilar developers rarely build dedicated plants; they buy capacity on contract and compete on cost of goods. That creates high-volume, price-sensitive demand within the Biopharmaceuticals Contract Manufacturing Market suited to CDMOs operating 15,000–20,000-liter [bioreactor](https://www.marketresearchfuture.com/reports/bioreactor-market-43158) trains. Interchangeability guidance from the FDA has also shortened the clinical burden for follow-on antibodies, accelerating launch timelines.

### Complexity of ADCs and Bispecifics

More than 15 antibody-drug conjugates now hold FDA approval, and hundreds more are in clinical development. ADCs require antibody production, high-potency payload handling, conjugation, and containment-grade fill-finish, a combination few sponsors maintain internally. Bispecific formats add expression and purification challenges. Sponsors increasingly award these programs to providers offering integrated suites, which raises contract values per molecule well above those of conventional mAbs.

### Single-Use and Continuous Manufacturing Adoption

ICH Q13, adopted in November 2022, gave regulators a harmonized framework for continuous manufacturing [3]. The FDA's Advanced Manufacturing Technologies Designation Program, finalized in 2024, offers early engagement for qualifying platforms. Contract manufacturers use these tools to run intensified perfusion processes that can deliver three to five times the volumetric output of fed-batch runs, lowering cost per gram and freeing capacity for additional clients.

### Government Biomanufacturing Programs

The US National Biotechnology and Biomanufacturing Initiative, launched in 2022, committed over USD 2 billion across federal agencies to domestic production capacity [11]. India's Production Linked Incentive scheme for pharmaceuticals allocated INR 15,000 crore, including biologics. South Korea targets a leading global position in biomanufacturing capacity through its bio-health strategy [15]. These programs de-risk greenfield construction and draw contract work toward supported locations.

## Restraints

## Restraints Impact Analysis

Restraint percentages are directional and indicate downward pressure on growth. They overlap with each other and with drivers, so they should not be summed against the CAGR.

| Restraint | ~% Impact on CAGR | Geographic Relevance | Impact Timeline | Ref |
| --- | --- | --- | --- | --- |
| Regulatory compliance burden and inspection findings | -1.2% | Global | Long-term (≥4 yr) |   |
| Capacity overbuild and pricing pressure | -0.9% | North America, South Korea | Medium-term (2–4 yr) | [5] |
| Shortage of skilled bioprocess workforce | -0.8% | North America, Europe | Long-term (≥4 yr) | [17] |
| Technology transfer delays and IP risk | -0.6% | Global | Short-term (≤2 yr) | [18] |
| Trade tariffs and geopolitical disruption | -0.7% | US, China, Europe | Short-term (≤2 yr) | [19] |

### Regulatory Compliance Burden and Inspection Findings

FDA warning letters and Form 483 observations at contract locations may delay permits for all clients sharing a facility. Remediation usually takes 12–24 months, and it involves a lot of quality-system spend. Providers with a history of inspections see sales cycles extended and volumes broken up as sponsors push back with audit rights and dual-sourcing.

### Capacity Overbuild and Pricing Pressure

Bioreactor capacity additions announced by the industry since 2022 are in the hundreds of thousands of liters, including 180,000 liters from Samsung Biologics at Plant 5 alone [5]. If the need for biosimilar and commercial products ramps up slower than predicted, utilization across the Biopharmaceuticals Contract Manufacturing Market declines, and large-scale mammalian pricing softens. Mid-sized suppliers without differentiated modalities get squeezed first.

### Shortage of Skilled Bioprocess Workforce

US and European biomanufacturing employers find sustained deficits in upstream, downstream and quality roles [17]. The new facilities need hundreds of trained operators and QA professionals before validation can start. Operating expenses are pushed up by pay rises for experienced staff, while staff turnover increases deviation rates and delays batch release.

### Technology Transfer Delays and IP Risk

Moving a procedure from one site to another is normally a 12-18 month process, and comparability problems can lead to further clinical bridging [18]. Sponsors are also concerned about securing proprietary cell lines and process know-how. It slows initial outsourcing decisions and favors incumbent providers, minimizing contract churn that would otherwise expand addressable work.

### Trade Tariffs and Geopolitical Disruption

The initiation of US tariff investigations into pharmaceutical imports under Section 232 in 2025 [19] increased uncertainty over cross-border supply of therapeutic substances. Some sponsors delayed decisions on awards pending clarification of duties. Export restriction tensions between the US and China add to the sourcing headache for reagents, resins and single-use components.

## Opportunities

## Biopharmaceuticals Contract Manufacturing Market Opportunities

### GLP-1 and Peptide Fill-Finish Capacity

Demand for semaglutide and tirzepatide outstripped supply through 2024, and Novo Holdings' purchase of Catalent was driven largely by fill-finish needs [1]. Players in the Biopharmaceuticals Contract Manufacturing Market able to offer peptide drug substance, high-speed autoinjector filling, and device assembly can secure long-dated commercial agreements. Next-generation oral and multi-agonist incretins will extend this demand well into the next decade.

### Emerging-Market Capacity in India and Southeast Asia

India's PLI support and lower construction costs create room for cost-competitive biosimilar and vaccine capacity. Providers with FDA- and EMA-inspected Indian sites can serve price-sensitive global tenders. The opportunity extends to WHO-backed regional vaccine manufacturing hubs in Africa and South America, which seek technology partners [20].

### Cell and Gene Therapy Vector Capacity

GMP viral-vector capacity remains scarce, and the FDA approved multiple new gene therapies in 2023 and 2024. Specialized providers that standardize AAV and lentiviral platforms can command premium margins. Converting bespoke processes into reusable platform workflows also shortens timelines for repeat customers.

### Data Monetization and Risk-Sharing Business Models

Process data generated across hundreds of client batches is a monetizable asset when anonymized and used to train predictive models for titer, yield, and deviation risk. Some providers now pair manufacturing with milestone- or royalty-linked fees, sharing development risk with cash-constrained biotechs. Digital batch records and real-time release analytics underpin these models.

### Integrated ADC Conjugation Suites

Few sites can handle antibody production, payload synthesis, and conjugation under one quality system. Building integrated, high-containment ADC suites lets providers capture the full value chain and reduce transfer risk between vendors.

## Future Outlook

## Biopharmaceuticals Contract Manufacturing Market Future Outlook

### AI-Driven Process Development and Digital Twins

Machine learning applied to cell-line selection, media design, and process control will compress development timelines. Digital twins of bioreactors allow providers to run virtual experiments before committing GMP slots. The FDA's discussion papers on AI in drug manufacturing signal growing regulatory openness, and early adopters expect measurable gains in right-first-time batch rates.

### Modular and Continuous Manufacturing

Facility design is shifting toward prefabricated cleanroom modules and single-use bioprocessing that can be deployed in under two years. Continuous capture and polishing steps under ICH Q13 [3] will reduce footprint and cost of goods. Smaller, intensified plants will let providers serve regional markets without building 20,000-liter trains.

### Regionalized Supply Networks

Sponsors are designing "in-region, for-region" supply strategies after pandemic disruption and trade friction. Expect multi-site agreements spanning the US, Europe, and a qualified Asian source as standard practice. Contract providers with global networks and harmonized quality systems will win the largest frame agreements in the Biopharmaceuticals Contract Manufacturing Market.

### Sustainability and Emissions Reporting

Healthcare accounts for roughly 4–5% of global greenhouse gas emissions [24], and pharmaceutical sponsors are pushing Scope 3 targets onto suppliers. Single-use plastic waste, water intensity, and energy use in cleanrooms will become contract criteria. Providers investing in renewable power and plastic recycling programs will gain an edge in tenders from large pharma clients.

## Segment Insights

## Biopharmaceuticals Contract Manufacturing Market Segmentation

### By Product Type

| Segment | Key Metric (2025) | Primary Demand Driver |
| --- | --- | --- |
| Peptides/Proteins | USD 9.43 Billion | GLP-1 and recombinant protein demand |
| Antibodies (mAbs & ADCs) | 35.4% share | Oncology and immunology pipelines |
| Vaccines | 11.2% CAGR (2026–2035) | Pandemic preparedness and new vaccine launches |
| Biosimilars | 12.6% share | Patent expiries of major antibodies |
| Other Biologics | 16.5% CAGR (2026–2035) | Cell and gene therapy commercialization |

Antibodies (mAbs & ADCs) remain the anchor of the Biopharmaceuticals Contract Manufacturing Market, supported by high-volume oncology and autoimmune programs and rising ADC complexity. Other Biologics, which include cell and gene therapy vectors, grow fastest because GMP vector capacity is scarce and highly specialized. Peptides/Proteins gain from GLP-1 demand, while Biosimilars build volume ahead of the 2028–2031 expiry window. Vaccines provide steady but lower growth after pandemic normalization.

### By Service Type

| Segment | Key Metric (2025) | Primary Demand Driver |
| --- | --- | --- |
| Process Development | 14.6% CAGR (2026–2035) | Outsourced CMC by early-stage biotechs |
| cGMP Drug Substance Manufacturing | 46.8% share | Commercial and late-stage volume |
| Fill-Finish & Lyophilization | USD 7.32 Billion | Injectable and autoinjector demand |
| Analytical & QC Services | 13.1% CAGR (2026–2035) | Complex modality characterization |
| Packaging & Logistics | 5.9% share | Cold-chain and serialization needs |

cGMP Drug Substance Manufacturing generates the largest share of the Biopharmaceuticals Contract Manufacturing Market because commercial batches carry the highest contract values. Process Development grows fastest as venture-backed companies outsource cell-line work, scale-up, and tech transfer from day one. Fill-Finish & Lyophilization benefits from GLP-1 and biologic injectables, while Analytical & QC Services expand with ADC and vector characterization requirements.

### By Expression System

| Segment | Key Metric (2025) | Primary Demand Driver |
| --- | --- | --- |
| Mammalian | 58.6% share | Glycosylated proteins and complex mAbs |
| Microbial | USD 14.86 Billion | Cost-efficient recombinant proteins and peptides |
| Insect & Plant | 13.4% CAGR (2026–2035) | Niche vaccines and novel protein platforms |

Mammalian systems, chiefly CHO cells, hold the leading share of the Biopharmaceuticals Contract Manufacturing Market because glycosylated antibodies require human-compatible post-translational modification. Microbial platforms remain the cost-efficient choice for simpler proteins, enzymes, and some peptides. Insect & Plant systems grow fastest from a small base, supported by baculovirus-produced vaccines, though limited regulatory familiarity still restricts broader adoption.

### By Development Phase

| Segment | Key Metric (2025) | Primary Demand Driver |
| --- | --- | --- |
| Pre-clinical | 14.1% CAGR (2026–2035) | Venture-funded discovery pipelines |
| Phase I | USD 4.27 Billion | First-in-human batch demand |
| Phase II | 12.9% CAGR (2026–2035) | Fast scale-up and validated analytics |
| Phase III & Commercial | 61.3% share | Multi-year supply agreements |

Phase III & Commercial projects form the revenue backbone of the Biopharmaceuticals Contract Manufacturing Market, providing multi-year volume commitments that justify large bioreactor installations. Pre-clinical work grows fastest as startups outsource nearly all CMC activities and run proof-of-concept batches in 50–200-liter single-use systems. Phase II demand rewards providers offering seamless scale-up within one quality system.

## Regional Market Share Analysis

## Regional Market Share Analysis

| Region | Key Metric (2025) | Primary Investment Themes |
| --- | --- | --- |
| North America | 38.6% share | Reshoring, ADC suites, commercial mAb capacity |
| Europe | USD 12.75 Billion | Site acquisitions, cell and gene therapy, fill-finish |
| Asia Pacific | 15.1% CAGR (2026–2035) | Mega-scale mammalian plants, biosimilars |
| South America | 4.6% share | Vaccine technology transfer, biosimilars |
| Middle East and Africa | USD 1.93 Billion | Vaccine sovereignty, localization mandates |
| Total | USD 44.90 Billion | — |

Regional demand in the Biopharmaceuticals Contract Manufacturing Market follows pipeline density, regulatory credibility, and government incentives. North America holds the largest share, while Asia Pacific grows fastest as Korean and Indian capacity comes online.

### North America

| Country | Key Metric (2025) | Key Driver |
| --- | --- | --- |
| United States | 84.5% share of region | Largest biotech pipeline and onshoring incentives |
| Canada | USD 1.82 Billion | Federal biomanufacturing strategy funding |
| Mexico | 13.6% CAGR (2026–2035) | Nearshoring of fill-finish and packaging |

The United States dominates North American demand in the Biopharmaceuticals Contract Manufacturing Market because most emerging biotechs are headquartered there and FDA approval remains the commercial gateway. Capacity investments by Fujifilm in North Carolina and Lonza in California [12] directly respond to sponsors seeking domestic supply. Canada's Biomanufacturing and Life Sciences Strategy has funded vaccine and biologics plants since 2021, while Mexico attracts secondary packaging work tied to North American supply chains.

### Europe

| Country | Key Metric (2025) | Key Driver |
| --- | --- | --- |
| Germany | 24.8% share of region | Large-scale mammalian and ADC capacity |
| United Kingdom | USD 2.18 Billion | Cell and gene therapy catapult ecosystem |
| France | 11.4% CAGR (2026–2035) | France 2030 health sovereignty funding |
| Italy | 10.6% share of region | Fill-finish and sterile manufacturing base |
| Spain | 12.2% CAGR (2026–2035) | Biosimilar and vaccine investment |
| Rest of Europe | USD 2.89 Billion | Swiss and Irish biologics clusters |

Germany anchors the European Biopharmaceuticals Contract Manufacturing Market footprint through Boehringer Ingelheim and Rentschler Biopharma sites. The European Commission's 2023 pharmaceutical reform package seeks to strengthen supply security and production within the bloc. France has earmarked biomanufacturing funding under France 2030, and the UK's cell and gene therapy infrastructure supports specialized vector work. Ireland and Switzerland, captured in Rest of Europe, host large multinational and CDMO plants.

### Asia Pacific

| Country | Key Metric (2025) | Key Driver |
| --- | --- | --- |
| China | 34.2% share of region | Domestic biotech boom and biosimilar demand |
| Japan | USD 1.71 Billion | Government vaccine production subsidies |
| India | 17.8% CAGR (2026–2035) | PLI incentives and biosimilar exports |
| South Korea | 18.9% share of region | Mega-scale contract plants in Songdo |
| Australia | 13.8% CAGR (2026–2035) | mRNA and clinical-stage manufacturing |
| Rest of Asia Pacific | USD 0.98 Billion | Singapore biologics hub |

Asia Pacific posts the fastest growth in the Biopharmaceuticals Contract Manufacturing Market as South Korea's Songdo cluster scales, and India attracts diversification contracts. Samsung Biologics' Plant 5 [5] and Celltrion's expansions reinforce Korea's role as a global supplier. China retains a large domestic customer base, although US legislative scrutiny is shifting some Western contracts elsewhere [2]. India's PLI scheme and Japan's vaccine manufacturing subsidies broaden the regional supply map.

### South America

| Country | Key Metric (2025) | Key Driver |
| --- | --- | --- |
| Brazil | 58.4% share of region | Public-private technology transfer partnerships |
| Argentina | 11.9% CAGR (2026–2035) | Biosimilar production and WHO mRNA hub role |
| Rest of South America | USD 0.41 Billion | Regional vaccine procurement |

Brazil leads through productive development partnerships that transfer biologics know-how to Fiocruz and Butantan. Argentina's Sinergium was selected as a WHO mRNA technology hub partner, positioning the country for vaccine contract work [20]. Biosimilar uptake in public health systems sustains demand for cost-efficient antibody production across the region.

### Middle East and Africa

| Country | Key Metric (2025) | Key Driver |
| --- | --- | --- |
| GCC | 14.7% CAGR (2026–2035) | Localization mandates in Saudi Arabia and UAE |
| South Africa | 27.3% share of region | WHO mRNA hub and vaccine fill-finish |
| Rest of Middle East and Africa | USD 0.62 Billion | African Vaccine Manufacturing Accelerator |

Gulf states are building local biologics capacity as part of health-security and economic-diversification plans. South Africa hosts the WHO mRNA technology transfer hub at Afrigen [20]. Gavi's African Vaccine Manufacturing Accelerator, with up to USD 1.2 billion in incentives, aims to lift the continent's share of locally produced vaccines [23].

## Competitive Benchmarking

## Competitive Benchmarking

The Biopharmaceuticals Contract Manufacturing Market shows low concentration, with an estimated Herfindahl-Hirschman Index of 650–850. The top five providers together hold roughly 36–42% of revenue, while hundreds of regional and modality-specialist firms share the remainder. Scale leaders compete on large-volume mammalian capacity and regulatory track record, while specialists win on vectors, conjugation, and speed.

| Company | Est. Revenue Share Range | Key Offerings for Biopharmaceuticals Contract Manufacturing Market | Strategic Positioning |
| --- | --- | --- | --- |
| Lonza Group | ~9–12% | Mammalian, microbial, cell and gene, bioconjugates | Global scale leader with integrated modality coverage |
| Samsung Biologics | ~7–10% | Large-scale mammalian drug substance, fill-finish, ADC | Capacity leader focused on commercial mAbs |
| WuXi Biologics | ~6–9% | End-to-end discovery to commercial biologics | Integrated platform facing Western sourcing scrutiny |
| Thermo Fisher Scientific (Patheon) | ~5–8% | Drug substance, fill-finish, viral vectors | Broad network tied to clinical services |
| Boehringer Ingelheim BioXcellence | ~4–6% | Mammalian and microbial production, fill-finish | Pharma-backed quality and scale |
| Fujifilm Diosynth Biotechnologies | ~4–6% | kojoX modular mammalian capacity, gene therapy | Rapid US and European capacity expansion |
| Catalent (Novo Holdings) | ~3–5% | Biologics, fill-finish, gene therapy | Repositioning after acquisition by Novo Holdings |
| AGC Biologics | ~2–4% | Mammalian, microbial, mRNA, cell and gene | Multi-modality mid-tier player |
| Rentschler Biopharma | ~1–3% | Complex protein and mAb manufacturing | Family-owned specialist in difficult molecules |
| Celltrion | ~1–3% | Contract mAb and biosimilar production | Biosimilar expertise with Korean scale |

## Recent News & Developments

## Recent News & Developments

- Novo Holdings (December 2024): Completed its USD 16.5 billion acquisition of Catalent, with three fill-finish sites transferred to Novo Nordisk to expand GLP-1 supply [1].
- Lonza (October 2024): Closed the USD 1.2 billion acquisition of Genentech's Vacaville, California biologics site, adding roughly 330,000 liters of mammalian capacity [12].
- US House of Representatives (September 2024): Passed the BIOSECURE Act, prompting sponsors to reassess suppliers linked to designated biotechnology companies [2].
- Fujifilm Diosynth Biotechnologies (April 2024): Announced an additional USD 1.2 billion investment in Holly Springs, North Carolina, expanding large-scale cell culture capacity.
- Samsung Biologics (April 2025): Began operating Plant 5 with 180,000 liters of capacity at Bio Campus II in Songdo [5].
- WuXi Biologics (January 2025): Agreed to sell its Irish vaccine facility to Merck, refocusing its European footprint.
- US Food and Drug Administration (2024): Finalized guidance for the Advanced Manufacturing Technologies Designation Program to speed adoption of novel production methods.

## Report Scope

| Parameter | Details |
| --- | --- |
| Market Scope | Outsourced development, drug substance manufacturing, fill-finish, analytical, and packaging services for peptides, antibodies, vaccines, biosimilars, and other biologics across all development phases |
| Study Period | 2021–2035 |
| Base Year | 2025 |
| Historical Data | 2021–2024 |
| Forecast Period | 2026–2035 |
| Market Size in 2025 | USD 44.90 Billion |
| Market Size in 2035 | USD 144.96 Billion |
| CAGR (2026–2035) | 12.45% |
| Fastest Growing Segments | Other Biologics (16.5% CAGR); Process Development (14.6% CAGR); Pre-clinical (14.1% CAGR); Insect & Plant (13.4% CAGR) |
| Regions Covered | North America, Europe, South America, Asia Pacific, Middle East and Africa and ROW |
| Companies Profiled | Lonza Group, Samsung Biologics, WuXi Biologics, Thermo Fisher Scientific, Boehringer Ingelheim BioXcellence, Fujifilm Diosynth Biotechnologies, Catalent, AGC Biologics, Rentschler Biopharma, Celltrion |
| Valuation Currency | USD Billion |
| Methodology | 350+ primary expert interviews; bottom-up market sizing; top-down validation; data triangulation; scenario-based forecasting; real-time project tracking |

## Frequently Asked Questions

**Q: How should sponsors evaluate a partner in the Biopharmaceuticals Contract Manufacturing Market?**
A: Inspection history matters most, so review FDA Form 483s and warning letters before shortlisting [16]. Then confirm the provider can scale your modality without a site transfer.

**Q: What contract structures are common for commercial supply?**
A: Commercial deals in the Biopharmaceuticals Contract Manufacturing Market usually run five to ten years with minimum annual batch commitments. Take-or-pay clauses protect the provider, while price-adjustment and technology-progress terms protect the sponsor [6].

**Q: Does the Biopharmaceuticals Contract Manufacturing Market favor single-site or multi-site sourcing?**
A: Multi-site sourcing is becoming standard for commercial products. Qualifying a second site adds cost but limits exposure to inspection failures, tariffs, and regional disruption [2].

**Q: How long does a typical technology transfer take?**
A: Most transfers take 12 to 18 months, including engineering runs and process performance qualification batches [18]. Comparability gaps can add further months if bridging studies are needed.

**Q: What risks do investors watch in the Biopharmaceuticals Contract Manufacturing Market?**
A: Utilization is the key risk because idle bioreactors erode margins fast. Investors also track client concentration and regulatory exposure, since one warning letter can stall several programs [5].

**Q: Are mRNA platforms relevant to contract manufacturers after the pandemic?**
A: Yes, mainly for oncology vaccines and regional pandemic preparedness. WHO-supported hubs are transferring mRNA know-how to manufacturers in Africa, Asia, and South America [20].

**Q: How do biosimilar developers keep cost of goods low?**
A: They pair high-titer cell lines with large-scale bioreactors and intensified processes. Buying contract capacity instead of building plants also keeps fixed costs off the balance sheet [9].


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/biopharmaceuticals-contract-manufacturing-market-43552*